Table 1.
Baseline characteristics of patients with and without diabetes. Categorical data presented as total numbers (%). Numeric data is presented as mean (SD) or median (IQR)
| Diabetes n = 681 (29.5%) |
No Diabetes n = 1630 (70.5%) |
p-value | n | |
|---|---|---|---|---|
| 28-day case fatality (%) | 50 (7.3) | 104 (6.4) | 0.451 | 2311 |
| Total number of cases with information on long-term survival (row percentage) | 561 (29.8) | 1323 (70.2) | 1884 | |
| Number of deaths between 28 days and 5 years (%) | 127 (25.7) | 133 (11.5) | < 0.001 | 1650 |
| Number of deaths after 28 days (%) | 188 (33.5) | 245(18.5) | < 0.001 | 1884 |
| Sex (male) | 481 (70.6) | 1203 (73.8) | 0.1305 | 2311 |
| Age (mean, SD) | 68 (11) | 63.7 (12.7) | < 0.001 | 2311 |
| Admission Glucose (mg/dl) (median, IQR) | 178 (142–237) | 125 (108–150) | < 0.001 | 2311 |
| HbA1c (%) (median, IQR) | 6.6 (6–7.5) | 5.6 (5.4–5.9) | < 0.001 | 2311 |
| HbA1c (mmol/mol) (median, IQR) | 48.6 (42.0–58.5) | 37.7 (35.5–41.0) | < 0.001 | 2311 |
| SHR (median, IQR) | 1.2 (1.0–1.5) | 1.1 (1.0–1.3) | < 0.001 | 2311 |
| Comorbidities and risk factors | ||||
| Hypertension | 611 (89.7) | 1168 (71.7) | < 0.001 | 2311 |
| Hyperlipidemia | 416 (61.1) | 796 (48.8) | < 0.001 | 2311 |
| Smoking status | ||||
| - Current smoker | 170 (25) | 590 (36.2) | < 0.001 | 2311 |
| - Never smoker | 210 (30.8) | 431 (26.4) | – | – |
| - Ex smoker | 232 (34.1) | 452 (27.7) | – | – |
| - No information on smoking | 69 (10.1) | 157 (9.6) | – | – |
| Clinical characteristics | ||||
| Typical chest pain symptoms | 570 (83.7) | 1403 (86.1) | 0.2415 | 2311 |
| Prehospital time in minutes (median, IQR) | 139.5 (76.8–350) | 122.5 (79–297.5) | 0.0867 | 1996 |
| Type of infarction | ||||
| - STEMI | 355 (52.1) | 970 (59.5) | 0.0028 | 2311 |
| - NSTEMI | 260 (38.2) | 556 (34.1) | – | – |
| - BBB | 51 (7.5) | 78 (4.8) | – | – |
| - No information on infarction type | 15 (2.2) | 26 (1.6) | – | – |
| Renal function | ||||
| - GFR > = 60 ml/min | 382 (56.1) | 1150 (70.6) | < 0.001 | 2311 |
| - GFR 30-59 ml/min | 246 (36.1) | 425 (26.1) | – | – |
| - GFR < 30 ml/min | 53 (7.8) | 55 (3.4) | – | – |
| LVEF | ||||
| - > 50% | 295 (43.3) | 798 (49) | 0.0498 | 2311 |
| - 41–50% | 140 (20.6) | 319 (19.6) | – | – |
| - 31–40% | 150 (22) | 302 (18.5) | – | – |
| - ≤ 30% | 65 (9.5) | 123 (7.5) | – | – |
| - No information | 31 (4.6) | 88 (5.4) | – | – |
| Any in-hospital complication | 172 (25.3) | 395 (24.2) | 0.6395 | 2311 |
| Days at intensive care (mean, SD) | 3.2 (5.2) | 2.9 (4.6) | 0.1705 | 2293 |
| Days at intensive care (median, IQR) | 2 (1–3) | 2 (1–3) | 0.1705 | 2293 |
| Laboratory values | ||||
| Admission hemoglobin (g/l) (median, IQR) | 139 (126–150) | 143 (132–152) | < 0.001 | 2311 |
| Admission troponin I (ng/ml) (median, IQR) | 0.680 (0.13–6.35) | 0.605 (0.11–4.6575) | 0.8477 | 1951 |
| Admission CRP (mg/dl) (median, IQR) | 0.55 (0.29–1.45) | 0.34 (0.29–0.85) | 0.0507 | 2311 |
| Therapy | ||||
| PCI | 571 (83.8) | 1401 (86) | 0.2426 | 2311 |
| Bypass therapy | 90 (13.2) | 188 (11.5) | 0.4261 | 2311 |
| Lysis therapy | 4 (0.6) | 15 (0.9) | 0.702 | 2311 |
| Any revascularization therapy | 639 (93.8) | 1539 (94.4) | 0.6512 | 2311 |
| All four evidence-based medications at discharge | 510 (74.9) | 1260 (77.3) | 0.2325 | 2311 |